Open an account

Opus Genetics

IRD · NASDAQ

$4.01+$0.19 (+4.97%)TodayMarket closed ·
Prev close $3.82

About IRD

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 27 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Employees
27
Headquarters
Durham, North Carolina
Listed
Nov 30, 2004
Sector
Health Care
Industry
Biotechnology
Website
opusgtx.com

IRD key statistics

Market cap
333.62M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.88M
Volume
1.46M
Open price
$3.82
High today
$4.15
Low today
$3.78
52 Week high
$7.07
52 Week low
$1.70

Opus Genetics (IRD) at a glance

Opus Genetics (IRD) last traded at $4.01, with a market cap of 333.62M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.78 and $4.15. The current price is 6.1% above the day's low and 3.3% below its high.

Volume so far is 1.46M shares, below the average of 1.88M shares a day.

Over the past year Opus Genetics has ranged from $1.70 to $7.07, and now sits 43% of the way up that range.

Opus Genetics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.1583.

The average analyst price target is $12.98, 223.6% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 14 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 19 analystsAvg $12.98
Low
$8.08
Now
$4.01
High
$21.00

IRD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 27.9% on average.

  1. Q3 FY24: reported -$0.29 per share against an estimate of -$0.2399
  2. Q4 FY24: reported -$0.22 per share against an estimate of -$0.2592
  3. Q1 FY25: reported -$0.24 per share against an estimate of -$0.2525
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.2071
  5. Q3 FY25: reported -$0.25 per share against an estimate of -$0.1313
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.1175
  7. Q1 FY26: reported -$0.75 per share against an estimate of -$0.1439
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.1583

IRD news

  • Press releaseGlobe Newswire

    Big Pharma Setbacks Create a New Wave of Rebound Plays

  • Avi Kapoor

    Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings

  • Press releaseGlobe Newswire

    Four Biotech Stories Heating Up Right Now

  • Vandana Singh

    Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

  • Avi Kapoor

    Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Where Opus Genetics Stands With Analysts

  • Where Opus Genetics Stands With Analysts

Similar companies

Companies in the same industry as Opus Genetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.